公共资金面临压力，生物技术革新者正在肿瘤学领域弥补不足-动脉网

With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology

CISION 等信源发布 2025-06-20 21:21



可切换为仅中文







USA

美国

News Group

新闻组

News Commentary

新闻评论

Issued on behalf of Oncolytics Biotech Inc.

代表 Oncolytics Biotech Inc. 发布。

VANCOUVER, BC

温哥华，不列颠哥伦比亚省

，

June 20, 2025

2025年6月20日

/PRNewswire/ --

USA

美国

News Group

新闻组

News Commentary

新闻评论

– The costs of cancer drugs is skyrocketing, according to a

– 癌症药物的费用正在飙升，

recent report

最近的报告

from

从

Bloomberg

彭博社

. Analysts at

. 分析师在

Nova One Advisor

新星一号顾问

estimate that the

估计那个

global oncology drugs market

全球肿瘤药物市场

will grow at a 7.4% CAGR through to

将以7.4%的年均复合增长率增长，直至

US$366.24 billion

3662.4亿美元

by 2034. Help doesn't appear to be coming from the public sector, as

到2034年。帮助似乎不会来自公共部门，因为

reports

报告

state that the current US administration could

声明称，美国现政府可能

drastically reduce funding

大幅削减资金

of the

的

National Cancer Institute (NCI)

国家癌症研究所 (NCI)

by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For investors to note, plenty of oncology innovators have provided recent developments, including

几乎下降了40%，市场正寄希望于私营部门来弥补这一缺口，并继续在癌症治疗方面取得进展。投资者应注意，许多肿瘤学创新者近期已提供了相关进展，包括

Oncolytics Biotech Inc.

Oncolytics生物技术公司

(NASDAQ:

（纳斯达克：

ONCY

) (TSX: ONC),

) (多伦多证券交易所：ONC)，

Immuneering Corporation

免疫工程公司

(NASDAQ:

（纳斯达克：

IMRX

GRAIL, Inc.

GRAIL公司

(NASDAQ:

（纳斯达克：

GRAL

通用机器人抽象层

Intensity Therapeutics, Inc.

强度治疗公司

(NASDAQ:

（纳斯达克：

INTS

整数集

), and

），并且

Relay Therapeutics, Inc.

中继治疗公司

(NASDAQ:

（纳斯达克：

RLAY

）。

继续阅读

With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology

公共资金面临压力，生物技术创新者正在填补肿瘤学领域的空缺。

Pelareorep Factsheet

Pelareorep 事实表

The global oncology market is expected to see strong growth over the next decade, with

全球肿瘤学市场预计在未来十年将实现强劲增长，

ResearchAndMarkets

研究与市场

forecasting

预测

it to reach

它到达

US$866.1 billion

8661亿美元

by 2034 at a 10.8% CAGR. A separate estimate from

到2034年，年均复合增长率为10.8%。另一项估计来自

Vision Research Reports

视觉研究报道

projects

项目

the market will surpass

市场将超越

US$903.81 billion

9038.1亿美元

by the same year, growing at a 10.9% CAGR.

同年，以10.9%的年均复合增长率增长。

Oncolytics Biotech Inc.

Oncolytics生物技术公司

(NASDAQ:

（纳斯达克：

ONCY

) (TSX: ONC) has entered a new phase of leadership with the

) (TSX: ONC) 已进入领导的新阶段，伴随着

appointment

预约

的

Jared Kelly

杰瑞德·凯利

as Chief Executive Officer and member of the Board. Kelly brings a background in high-stakes biotech transactions and strategic immuno-oncology development, positioning him to guide the company through its next stage of clinical and business evolution.

作为首席执行官和董事会成员，凯利拥有高风险生物技术交易和战略免疫肿瘤学开发的背景，这使他能够引导公司进入临床和业务发展的下一个阶段。

Before joining

加入之前

Oncolytics

溶瘤病毒

, Kelly served as

，凯利担任了

General Counsel

总法律顾问

在

Ambrx Biopharma

Ambrx 生物制药

, where he played a key role in its

，他在其中发挥了关键作用

$2 billion

20亿美元

acquisition

收购

通过

Johnson & Johnson

强生公司

. His earlier work includes advising life sciences firms on licensing, partnerships, and M&A while at

他在早期的工作中包括在授权、合作和并购方面为生命科学公司提供咨询，当时他

Kirkland & Ellis LLP

柯克兰埃利斯律师事务所

and

和

Lowenstein Sandler LLP

洛温斯坦·桑德勒律师事务所

. Now leading

现在领先

Oncolytics

溶瘤病毒

, he steps into a company advancing pelareorep, a virus-based immunotherapeutic designed to work synergistically with checkpoint inhibitors and other agents across a range of solid and blood cancers.

，他加入了一家致力于推进pelareorep的公司，这是一种基于病毒的免疫疗法，旨在与检查点抑制剂和其他药物协同作用，治疗多种实体癌和血液癌症。

'Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients,' said .

“Pelareorep在多种肿瘤中的临床数据令人震惊，代表着一种真正的骨干免疫疗法的潜力，可以应对许多未满足需求的适应症。重要的是，数据显示Pelareorep在难以治疗的肿瘤中能够产生强大的免疫反应，并延长了历史上大多数患者无法存活的患者群体的生存期，”他表示。

Jared Kelly

贾里德·凯利

, CEO of

，首席执行官

Oncolytics Biotech

溶瘤生物技术

. 'With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders.'.

“通过重新聚焦和优化临床开发计划，我们相信我们将有效且高效地推进pelareorep，使潜在合作伙伴能够看到这种降低风险的免疫疗法的价值。我期待加快开发进程，为利益相关者释放重大价值。”

Kelly's appointment signals a clear strategic focus: advancing pelareorep toward key late-stage milestones through a capital-conscious approach that remains open to strategic collaboration.

凯利的任命表明了一个明确的战略重点：通过一种保持资本意识并开放于战略协作的方法，推动 pelareorep 达到关键的后期里程碑。

Pelareorep currently holds

Pelareorep 目前持有

FDA

食品药品监督管理局

Fast Track designation

快速通道指定

for both

适用于两者

metastatic pancreatic ductal adenocarcinoma (mPDAC)

转移性胰腺导管腺癌 (mPDAC)

and

和

HR+/HER2- metastatic breast cancer (mBC)

HR+/HER2-转移性乳腺癌（mBC）

—a rare dual recognition that underscores its regulatory momentum. Across multiple studies, the virus-based therapy has demonstrated consistent immune activation, broad combinability with checkpoint inhibitors and chemotherapies, and encouraging response rates in challenging cancer types.

——这一罕见的双重认可突显了其在监管方面的强劲势头。在多项研究中，这种基于病毒的疗法展现了持续的免疫激活、与检查点抑制剂和化疗药物广泛的组合潜力，以及在难治癌症类型中令人鼓舞的应答率。

在

mPDAC

, pelareorep has achieved

，pelareorep 已经实现

over 60% objective response rates

超过60%的客观缓解率

in tumor-evaluable patients across Phase 1 and 2 trials—more than double what's typically seen in

在第一和第二阶段试验中，可评估肿瘤的患者——是通常所见的两倍多

historical benchmarks

历史基准

. Separate analyses also reported two-year survival rates four to six times higher than control arms or prior studies. In

单独的分析还报告了两年生存率比对照组或之前的研究高出四到六倍。

HR+/HER2- mBC

HR+/HER2- 转移性乳腺癌

, two randomized Phase 2 trials (IND-213 and BRACELET-1) showed survival benefits supportive of further investigation.

，两项随机的二期试验（IND-213 和 BRACELET-1）显示了支持进一步研究的生存益处。

Meanwhile, a Phase 2 cohort in

同时，第二阶段的队列在

anal cancer

肛门癌

pairing pelareorep with a checkpoint inhibitor reported partial or complete responses in nearly half of evaluable patients—substantially higher than historical norms for monotherapy in this setting.

将 pelareorep 与检查点抑制剂联合使用，在近一半的可评估患者中报告了部分或完全缓解——显著高于此情况下单药治疗的历史标准。

'Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date,' said

“凯利先生的愿景和过往记录与pelareorep迄今为止产生的突出临床数据非常契合，”

Wayne Pisano

韦恩·皮萨诺

, Chair of the Board and outgoing Interim CEO of

，董事会主席兼即将离任的临时首席执行官

Oncolytics

溶瘤病毒

. 'We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors.'.

“我们相信，凯利先生在优先发展临床项目、成功融资以及吸引大型行业同行关注方面的能力将有助于最大限度地发挥Oncolytics为患者提供变革性成果和为投资者创造卓越价值的潜力。”

Kelly's compensation package includes equity grants and milestone-linked incentives tied to future financings and potential strategic transactions—aligning leadership priorities with long-term shareholder interests. The structure signals a commitment to advancing both clinical and corporate goals while preserving balance sheet discipline and maintaining appeal for potential partners..

凯利的薪酬方案包括股权授予以及与未来融资和潜在战略交易相关的里程碑激励——这使得领导层的优先事项与长期股东利益保持一致。该结构表明了在推进临床和企业目标的同时，坚持资产负债表纪律并保持对潜在合作伙伴吸引力的决心。

With multiple cohorts progressing in the GOBLET study—including those in pancreatic and anal cancer supported by external funding and regulatory engagement—

随着GOBLET研究中多个队列的推进——包括那些由外部资金和监管参与支持的胰腺癌和肛门癌队列——

Oncolytics

溶瘤学

is positioned to move forward with a combination of scientific momentum, financial agility, and renewed strategic focus.

凭借科学动力、财务灵活性和重新聚焦的战略，准备向前迈进。

CONTINUED… Read this and more news for Oncolytics Biotech at:

持续更新... 阅读更多关于Oncolytics Biotech的新闻，请访问：

https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/

https://usanewsgroup.com/2023/10/02/纳斯达克上最被低估的溶瘤公司/

In other recent industry developments and happenings in the market include:

其他近期行业发展和市场动态包括：

Immuneering Corporation

免疫工程公司

(NASDAQ:

（纳斯达克：

IMRX

) reported

）报道

positive Phase 2a data

积极的2a期数据

for atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. At six months, the study showed 94% overall survival and 72% progression-free survival in 34 patients, with no median OS or PFS reached yet.

对于atebimetinib（IMM-1-104）联合改良吉西他滨/白蛋白结合型紫杉醇用于一线胰腺癌患者的研究显示，在34名患者中，六个月时总体生存率为94%，无进展生存率为72%，尚未达到中位总生存期（OS）或无进展生存期（PFS）。

'These exceptional data demonstrate the potential of atebimetinib plus mGnP to dramatically extend the lives of patients with advanced pancreatic cancer,' said

“这些异常数据表明，atebimetinib 加 mGnP 有潜力大幅延长晚期胰腺癌患者的生命，”

Ben Zeskind

本·泽斯金德

, Ph.D., Co-founder and CEO of

，博士，联合创始人兼首席执行官

Immuneering

免疫工程

. 'Our ultimate goal is to help cancer patients outlive their disease, and today's announcement represents an important milestone on that journey.'

“我们的最终目标是帮助癌症患者战胜疾病，延长生命，而今天的声明代表了这一旅程中的一个重要里程碑。”

The combination also demonstrated a 39% overall response rate, an 81% disease control rate, and a notably favorable tolerability profile. Many patients experienced deep, durable tumor regressions, including lesions rendered undetectable. The regimen was well tolerated, with an adverse event profile suggesting potential best-in-class positioning among MEK inhibitors..

该联合疗法还显示出39%的总体缓解率、81%的疾病控制率，以及显著良好的耐受性特征。许多患者经历了深度且持久的肿瘤缩小，包括病灶完全消失的情况。该治疗方案耐受性良好，其不良事件特征表明其可能在MEK抑制剂中具有最佳的定位潜力。

GRAIL, Inc.

GRAIL公司

(NASDAQ:

（纳斯达克：

GRAL

recently announced

最近宣布

strong top-line results from the PATHFINDER 2 registrational study evaluating its Galleri® multi-cancer early detection test in over 25,000 adults.

来自PATHFINDER 2注册研究的强劲顶级结果，该研究评估了其Galleri®多癌症早期检测测试在超过25,000名成人中的应用。

'We are delighted to see very encouraging performance of the Galleri MCED test as a cancer screening tool in broad intended use populations of asymptomatic adults over 50 years of age in both the PATHFINDER 2 study and the NHS-Galleri trial's prevalent screening round,' said

“我们很高兴看到Galleri MCED测试作为癌症筛查工具在PATHFINDER 2研究和NHS-Galleri试验的普遍筛查轮次中，针对50岁以上无症状成年人的广泛目标使用人群表现出非常令人鼓舞的性能，”

Josh Ofman

约什·奥夫曼

, MD, MSHS, President at

，医学博士，MSHS，总裁 at

GRAIL

圣杯

. 'We would like to extend our sincere gratitude to all of the participants and investigators in both of these pivotal studies, who are collectively helping to realize the potential of this groundbreaking technology for population-scale multi-cancer early detection and move the field forward.'

“我们衷心感谢这两项关键研究的所有参与者和研究人员，他们共同努力，正在帮助实现这项突破性技术在人群规模多癌症早期检测方面的潜力，并推动该领域向前发展。”

The study showed a substantially higher positive predictive value (PPV) compared to the original PATHFINDER trial, with consistent specificity and cancer signal origin accuracy, and no serious safety concerns reported.

该研究显示，与最初的 PATHFINDER 试验相比，阳性预测值 (PPV) 显著提高，特异性和癌症信号来源准确性保持一致，且未报告严重安全隐患。

GRAIL

圣杯

plans to submit these results to the

计划将这些结果提交给

FDA

食品药品监督管理局

as part of its ongoing premarket approval process under Breakthrough Device Designation.

作为其在突破性设备指定下持续进行的上市前审批流程的一部分。

Intensity Therapeutics, Inc.

Intensity Therapeutics公司

(NASDAQ:

（纳斯达克：

INTS

整数集

)

announced

宣布

that the first patients in its ongoing Phase 2 INVINCIBLE-4 trial achieved high levels of tumor necrosis within eight days of receiving two doses of INT230-6, before starting standard-of-care immunochemotherapy for triple-negative breast cancer (TNBC).

其正在进行的第 2 阶段 INVINCIBLE-4 试验中的首批患者在接受两剂 INT230-6 后八天内达到了高水平的肿瘤坏死，随后才开始针对三阴性乳腺癌 (TNBC) 的标准护理免疫化疗。

'We are excited to see that INT230-6 is achieving meaningful levels of necrosis in patients with evidence of immune activation,' said

“我们很高兴看到INT230-6在患者中实现了显著的坏死水平，并有免疫激活的证据，”

Lewis H. Bender

刘易斯·H·本德

, President and CEO of

，总裁兼首席执行官

Intensity

强度

. 'TNBC patients risk their lives to achieve a pCR, and about forty percent fail to achieve the desired result.'

“三阴性乳腺癌患者为了达到病理完全缓解（pCR）而冒着生命危险，但大约有40%的患者未能达到预期的效果。”

MRI scans showed substantial tumor destruction and inflammation, suggesting immune activation following direct intratumoral injection. The randomized study compares INT230-6 followed by standard treatment versus standard treatment alone, with pathological complete response (pCR) as the primary endpoint..

磁共振成像显示肿瘤出现明显破坏和炎症，表明直接瘤内注射后引起了免疫激活。这项随机研究比较了INT230-6联合标准治疗与单独标准治疗的差异，主要终点是病理完全缓解 (pCR)。

Relay Therapeutics, Inc.

继电器治疗公司

(NASDAQ:

（纳斯达克：

RLAY

)

reported updated interim data

报告了更新的中期数据

from its Phase 1/2 study of RLY-2608 plus fulvestrant, showing a median progression-free survival (PFS) of 11.0 months in second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer.

来自其RLY-2608联合氟维司群的1/2期研究，显示在PI3Kα突变、HR+/HER2-转移性乳腺癌二线患者中的中位无进展生存期（PFS）为11.0个月。

'We are encouraged by the consistency of these updated RLY-2608 + fulvestrant data, which continue to show the potential benefit of a mutant-selective PI3Kα inhibitor for improving both the tolerability profile and progression free survival compared to standard of care,' said

“我们对这些更新的RLY-2608 + 氟维司群数据的一致性感到鼓舞，这些数据继续显示出与标准治疗相比，选择性PI3Kα抑制剂在改善耐受性特征和无进展生存期方面的潜在益处，”

Don Bergstrom

唐·伯格斯特ром

, M.D., Ph.D., President of R&D at

，医学博士，哲学博士，研发部总裁 tại

Relay Therapeutics

继电器治疗公司

. 'We look forward to starting the first mutant-selective PI3Kα Phase 3 trial, ReDiscover-2, in the middle of this year.'

“我们期待在今年年中启动首个突变选择性PI3Kα三期试验ReDiscover-2。”

Among patients at the recommended Phase 3 dose, the clinical benefit rate reached 67%, and 39% had confirmed partial responses, with notably higher response rates in those with kinase mutations. The combination maintained a favorable tolerability profile, with low rates of high-grade adverse events and minimal treatment discontinuations..

在推荐的第三阶段剂量下的患者中，临床受益率达到67%，其中39%的患者确认部分缓解，携带激酶突变的患者缓解率显著更高。该组合疗法保持了良好的耐受性，高级别不良事件发生率较低，治疗中断情况极少。

Source:

来源：

https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/

CONTACT:

联系：

USA

美国

NEWS GROUP

新闻组

info@usanewsgroup.com

(604) 265-2873

DISCLAIMER:

免责声明：

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision.

本出版物中的任何内容均不应视为个性化的财务建议。我们并未根据证券法获得处理您特定财务状况的许可。我们员工与您的任何沟通均不应被视为个性化的财务建议。在做出任何投资决定之前，请咨询持有执照的财务顾问。

This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.

这是一则付费广告，既不是购买或出售任何证券的要约，也不是推荐。我们不持有任何投资许可证，因此没有资格提供投资建议。本报告或电子邮件中的内容并非针对任何个人的具体情况提供。

。

USA

美国

News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ('MIQ'). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock.

新闻集团是Market IQ Media Group, Inc.（“MIQ”）的全资子公司。MIQ已从Oncolytics Biotech Inc.直接获得广告和数字媒体费用。可能会有第三方持有Oncolytics Biotech Inc.的股份，并可能抛售其股票，这可能会对股价产生负面影响。

This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc.

这种补偿构成了我们对公司概况进行客观沟通的能力上的利益冲突。由于这一冲突，强烈建议个人不要将本出版物作为任何投资决策的基础。MIQ的所有者/运营商拥有Oncolytics Biotech Inc.的股份。

which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc.

这些股份是在公开市场上购买的，我们保留在任何时候买卖 Oncolytics Biotech Inc. 股票的权利，并将立即开始且持续进行买卖操作，不再另行通知。我们还预计会因持续的数字媒体推广活动而获得进一步报酬，以提高该公司的知名度，虽然不会另行通知，但请以此免责声明作为通知：所有由 MIQ 发布的材料，包括本文，均已获得 Oncolytics Biotech Inc. 的批准；这是一则付费广告，我们目前持有 Oncolytics Biotech Inc. 的股份。

and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles..

并将在公开市场上或通过私募方式和/或其他投资工具买卖该公司的股票。

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results.

虽然所有信息均被认为可靠，但我们不保证其准确性。个人应假设我们通讯中包含的所有信息均不可信，除非通过他们自己的独立研究进行核实。此外，由于事件和情况往往不会按预期发生，任何预测与实际结果之间可能会存在差异。

Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment..

在做出任何投资决定之前，请务必咨询持有执照的投资专业人士。请务必极其谨慎，证券投资具有高度风险，您可能会损失部分或全部投资。

Video -

视频 -

https://www.youtube.com/watch?v=ZCRCMliLC_E

Photo -

照片 -

https://mma.prnewswire.com/media/2715582/Pelareorep_Facts.jpg

Logo -

标志 -

https://mma.prnewswire.com/media/2603685/5380269/USA_News_Group_Logo.jpg

SOURCE

源